341 related articles for article (PubMed ID: 11708878)
1. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system.
Rubinchik S; Ding R; Qiu AJ; Zhang F; Dong J
Gene Ther; 2000 May; 7(10):875-85. PubMed ID: 10845726
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
4. New complex Ad vectors incorporating both rtTA and tTS deliver tightly regulated transgene expression both in vitro and in vivo.
Rubinchik S; Woraratanadharm J; Yu H; Dong JY
Gene Ther; 2005 Mar; 12(6):504-11. PubMed ID: 15660114
[TBL] [Abstract][Full Text] [Related]
5. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo.
Gu J; Zhang L; Huang X; Lin T; Yin M; Xu K; Ji L; Roth JA; Fang B
Oncogene; 2002 Jul; 21(31):4757-64. PubMed ID: 12101414
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
8. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
9. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
11. Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells.
Borrelli MJ; Schoenherr DM; Wong A; Bernock LJ; Corry PM
Cancer Res; 2001 Feb; 61(3):1113-21. PubMed ID: 11221841
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral vectors: regulated gene expression.
Kafri T; van Praag H; Gage FH; Verma IM
Mol Ther; 2000 Jun; 1(6):516-21. PubMed ID: 10933976
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
14. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.
Sipo I; Hurtado Picó A; Wang X; Eberle J; Petersen I; Weger S; Poller W; Fechner H
J Mol Med (Berl); 2006 Mar; 84(3):215-25. PubMed ID: 16437213
[TBL] [Abstract][Full Text] [Related]
15. Regulation of transgene expression using an inducible system for improved safety of intervertebral disc gene therapy.
Vadalà G; Sowa GA; Smith L; Hubert MG; Levicoff EA; Denaro V; Gilbertson LG; Kang JD
Spine (Phila Pa 1976); 2007 Jun; 32(13):1381-7. PubMed ID: 17545904
[TBL] [Abstract][Full Text] [Related]
16. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
17. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy.
Aoki K; Akyürek LM; San H; Leung K; Parmacek MS; Nabel EG; Nabel GJ
Mol Ther; 2000 Jun; 1(6):555-65. PubMed ID: 10933980
[TBL] [Abstract][Full Text] [Related]
18. Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.
Zhang L; Brereton HM; Hahn M; Froscio M; Tilley WD; Brown MP; Barritt GJ
Cancer Gene Ther; 2003 Aug; 10(8):611-25. PubMed ID: 12872143
[TBL] [Abstract][Full Text] [Related]
19. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
[TBL] [Abstract][Full Text] [Related]
20. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters.
Pluta K; Luce MJ; Bao L; Agha-Mohammadi S; Reiser J
J Gene Med; 2005 Jun; 7(6):803-17. PubMed ID: 15655804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]